Century Therapeutics, a biotechnology company, is expanding its autoimmune disease research through a $60 million private placement led by Bain Capital Life Sciences. Additionally, Century is acquiring Clade Therapeutics for $35 million, gaining preclinical programs and technology to enhance stem cell-derived medicines. The company aims to broaden its autoimmune disease work, focusing on natural killer cell therapy for lupus and other autoimmune conditions.

Clasp Therapeutics, a biotechnology company, launched with $150 million in financing led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings. The company aims to develop precise immuno-oncology treatments using next-generation T cell engagers. Clasp's modular TCEs target common oncogenic mutations, offering off-the-shelf, antibody-like medicines. The team includes Chief Executive Officer Robert Ross, M.D., and scientific founders Bert Vogelstein, M.D., and Drew Pardoll, M.D., Ph.D. from Johns Hopkins University. The financing round also saw participation from Vivo Capital, Cure Ventures, Blackbird BioVentures, Pictet Alternative Advisors, American Cancer Society’s Bright Edge, and Alexandria Venture Investments.

Clasp Therapeutics, a Johns Hopkins University biotech spinout, secured $150 million from investors like Catalio Capital Management, Third Rock Ventures, and Novo Holdings to advance its cancer treatment into clinical trials. The company, led by CEO Robert Ross, plans to establish a hub in Montgomery County and maintain a presence in Cambridge, Massachusetts. Clasp's focus is on solid tumors using a protein to target cancer cells, aiming to provide more effective treatments with fewer side effects.

Clasp Therapeutics and Capstan Therapeutics, both focused on developing treatments for various health conditions like cancer and autoimmune diseases, announced separate funding rounds totaling $325 million.

Clasp Therapeutics, an immuno-oncology startup with dual headquarters in Cambridge, Mass., and Rockville, Md., has raised $150 million led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings. The funding will support the company's clinical trials and provide initial proof-of-concept data. Robert Ross, previously from Surface Oncology and Bluebird Bio, serves as the CEO of Clasp Therapeutics.